Commentary on Meyers et al: Ethically prioritizing trials in the COVID-19 era - practical considerations

Romana Hasnain-Wynia^{1

2}, Matthew DeCamp^{2

3}, Marilyn Coors^{3

4}

Affiliations

¹ Office of Research, Denver Health & Hospital Authority, Denver, CO, USA.
² Division of General Internal Medicine, University of Colorado, Anschutz Medical Campus, Denver, CO, USA.
³ Center for Bioethics and Humanities, University of Colorado, Anschutz Medical Campus, Denver, CO, USA.
⁴ Department of Psychiatry, University of Colorado, Anschutz Medical Campus, Denver, CO, USA.

Comment

Romana Hasnain-Wynia et al. Clin Trials. 2021 Apr.

. 2021 Apr;18(2):234-236.

doi: 10.1177/1740774520988663. Epub 2021 Feb 2.

Romana Hasnain-Wynia^{1

2}, Matthew DeCamp^{2

3}, Marilyn Coors^{3

4}

¹ Office of Research, Denver Health & Hospital Authority, Denver, CO, USA.
² Division of General Internal Medicine, University of Colorado, Anschutz Medical Campus, Denver, CO, USA.
³ Center for Bioethics and Humanities, University of Colorado, Anschutz Medical Campus, Denver, CO, USA.
⁴ Department of Psychiatry, University of Colorado, Anschutz Medical Campus, Denver, CO, USA.

No abstract available

Comment on

An ethics framework for consolidating and prioritizing COVID-19 clinical trials.
Meyer MN, Gelinas L, Bierer BE, Hull SC, Joffe S, Magnus D, Mohapatra S, Sharp RR, Spector-Bagdady K, Sugarman J, Wilfond BS, Lynch HF. Meyer MN, et al. Clin Trials. 2021 Apr;18(2):226-233. doi: 10.1177/1740774520988669. Epub 2021 Feb 2. Clin Trials. 2021. PMID: 33530721 Free PMC article.